Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis

Bibliographic Details
Main Authors:	Kristine Paridaens, John R Fullarton, Simon P L Travis
Format:	Article
Language:	English
Published:	Wiley 2023-07-01
Series:	JGH Open
Subjects:	aminosalicylates delayed‐release effectiveness inflammatory bowel disease mesalamine
Online Access:	https://doi.org/10.1002/jgh3.12935

Similar Items

Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice
by: O. V. Knyazev, et al.
Published: (2021-10-01)

Not Your Typical Ulcerative Colitis Patient
by: Teodora SPATARU, et al.
Published: (2024-03-01)

Efficacy of mesalazine at ulcerative colitis with nutritional failure
by: A. V. Korolyov, et al.
Published: (2024-03-01)

Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01)

Acute granulomatous interstitial nephritis and ulcerative colitis: a case report and literature review
by: Giorgia Comai, et al.
Published: (2018-03-01)

An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
by: Francesca Ferretti, et al.
Published: (2022-04-01)

The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice
by: O. V. Knyazev, et al.
Published: (2019-10-01)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
by: Virginia Solitano, et al.
Published: (2020-09-01)

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
by: Gionata Fiorino, et al.
Published: (2019-05-01)

Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach
by: Christophi GP, et al.
Published: (2016-05-01)

The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis
by: Paridaens, K, et al.
Published: (2024)

Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?
by: Min Tang-Fichaux, et al.
Published: (2021-12-01)

Minimal change disease associated with balsalazide therapy for ulcerative colitis
by: Ahmad M. Al-Taee, et al.
Published: (2019-10-01)

Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
by: Gian Paolo Caviglia, et al.
Published: (2021-10-01)

Conjugation of Amisulpride, an Anti-Psychotic Agent, with 5-Aminosalicylic Acid via an Azo Bond Yields an Orally Active Mutual Prodrug against Rat Colitis
by: Wooseong Kim, et al.
Published: (2019-11-01)

Management and treatment of distal ulcerative colitis
by: Andrea Calafiore, et al.
Published: (2013-12-01)

5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis
by: Hyo Yeop Song, et al.
Published: (2022-01-01)

Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice
by: Qianyun Lin, et al.
Published: (2023-11-01)

USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES
by: M. V. Shapina, et al.
Published: (2017-11-01)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
by: Jihye Park, et al.
Published: (2022-09-01)

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
by: Mimari Kanazawa, et al.
Published: (2022-02-01)

Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind studyResearch in context
by: Nicholas Michael Croft, et al.
Published: (2023-11-01)

Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis
by: Shomron Ben-Horin, et al.
Published: (2022-09-01)

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis
by: Yan Yan, et al.
Published: (2019-12-01)

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
by: O. V. Knyazev, et al.
Published: (2021-05-01)

Repurposing a Drug Targeting Inflammatory Bowel Disease for Lowering Hypertension
by: Xue Mei, et al.
Published: (2022-12-01)

Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial
by: Jan Březina, et al.
Published: (2021-06-01)

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
by: Junyu Chen, et al.
Published: (2022-09-01)

Is Infection Associated With Ulcerative Colitis Activity?
by: Ayoung Lee, et al.
Published: (2024-03-01)

An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial.
by: Connolly, M, et al.
Published: (2009)

Ulcerative Colitis and Neopterin: Related?
by: Beşir Kesici, et al.
Published: (2019-04-01)

Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
by: Yamile Zabana, et al.
Published: (2022-12-01)

Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study
by: Maria Pina Dore, et al.
Published: (2023-07-01)

Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms
by: O. V. Knyazev, et al.
Published: (2022-08-01)

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)

Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
by: Soo-Young Na, et al.
Published: (2023-01-01)

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
by: Ferdinando D’Amico, et al.
Published: (2023-02-01)

What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?
by: Travis, S
Published: (2005)

Immunological Mechanism of Faecal Bacterial Transplantation in the Intervention of Ulcerative Colitis
by: WENG Jianfeng, XU Jia, LIU Peng, GE Wei, CHEN Jiaohua, PENG Yingying, HU Jiali, CUI Manman, ZHANG Leichang
Published: (2022-01-01)

Old but Fancy: Curcumin in Ulcerative Colitis—Current Overview
by: Aleksandra Pituch-Zdanowska, et al.
Published: (2022-12-01)